EXHIBIT 23.1

            Consent of Independent Registered Public Accounting Firm

The Board of Directors
Northwest Biotherapeutics, Inc.:

We consent to the incorporation by reference in the registration statement (No.
333-82094) on Form S-8 of Northwest Biotherapeutics, Inc. of our report dated
March 12, 2004, except as to note 2, which is as of April 26, 2004, with respect
to the statements of operations, stockholders' equity (deficit) and
comprehensive loss, and cash flows for the year ended December 31, 2003 and the
period from March 18, 1996 (inception) through December 31, 2003 of Northwest
Biotherapeutics, Inc. (a development stage company), which report appears in the
December 31, 2005 annual report on Form 10-K of Northwest Biotherapeutics, Inc.

Our report dated March 12, 2004, except as to note 2, which is as of April 26,
2004, contains an explanatory paragraph that states that Northwest
Biotherapeutics, Inc. has experienced recurring losses from operations, has a
working capital deficit and has a deficit accumulated in the development stage
which raise substantial doubt about its ability to continue as a going concern.
The financial statements do not include any adjustments that might result from
the outcome of that uncertainty.

/s/ KPMG LLP


Seattle, Washington
April 17, 2006